Colon specific delivery of miR-155 inhibitor alleviates estrogen deficiency related phenotype via microbiota remodeling

Lianbi Zhao, Tian Zhou, Jianmei Chen, Wenbin Cai, Ruijing Shi, Yunyou Duan, Lijun Yuan and Changyang Xing

Department of Ultrasound Diagnostics, Tangdu Hospital, Fourth Military Medical University, Xi’an, China

ABSTRACT
Compelling data have indicated menopause-associated increase in cardiovascular disease in women, while the underlying mechanisms remain largely unknown. It is established that changes of intestinal microbiota affect cardiovascular function in the context of metabolic syndrome. We here aimed to explore the possible link between host intestinal function, microbiota, and cardiac function in the ovariectomy (OVX) mouse model. Mice were ovariectomized to induce estrogen-related metabolic syndrome and cardiovascular defect. Microbiota was analyzed by 16s rRNA sequencing. miRNA and mRNA candidates expression were tested by qPCR. Cardiac function was examined by echocardiography. Colon specific delivery of miRNA candidates was achieved by oral gavage of Eudragit S100 functionalized microspheres. In comparison with the sham-operated group, OVX mice showed compromised cardiac function, together with activated inflammation in the visceral adipose tissue and heart. Lactobacillus abundance was significantly decreased in the gut of OVX mice. Meanwhile, miR-155 was mostly upregulated in the intestinal epithelium and thus the feces over other candidates, which in turn decreased Lactobacillus abundance in the intestine when endocytosed. Oral delivery of miR-155 antagonist restored the protective microbiota and thus protected the cardiac function in the OVX mice. This study has established a possible regulatory axis of intestinal miRNAs-microbiota-estrogen deficiency related phenotype in the OVX model. Colon specific delivery of therapeuic miRNAs would possibly restore the microbiota toward protective phenotype in the context of metabolic syndrome.

ARTICLE HISTORY
Received 17 April 2022
Revised 18 July 2022
Accepted 18 July 2022

KEYWORDS
Microbiota; cardiac function; miRNAs; colon specific drug delivery; metabolic syndrome

Introduction
Accumulating evidences underline the importance of the intestinal microbiota, which is considered as a kind of ‘external organ’, for the health of the host organism. It has been shown that the intestinal microbiota is a complex and dynamic ecosystem that influences host immunity and metabolism beyond the intestine (Kazemian et al., 2020; Liuzzo & Galiuto, 2021). The epidemic studies suggest that strong links between gut microbiota and cardiovascular disease (CVD) (Tang et al., 2017, 2019). For example, bacterial translocation and infiltration occur when the intestine is damaged (Chassaing et al., 2015). Besides, gut microbe-derived metabolites that are biologically active, such as trimethylamine N-oxide (TMAO), are now recognized as contributors to atherogenesis (Nam, 2019).

It has been well established that the risk for cardiovascular disease increases in women after menopause (Maas et al., 2021), which might be attributed to hormone change related obesity and the metabolic syndrome (MetS) (Barros & Gustafsson, 2011). Estrogen plays an important role in the control of energy homeostasis in females, while estrogen deficiency seems to have an unfavorable impact on mobilization of fatty acids, body fat distribution, and glucose-absorbing capacity of different tissues in post-menopausal women (Mauvais-Jarvis et al., 2013). Similarly, in ovariectomized mouse model, deprivation of estrogen leads to increases in fat mass, insulin resistance and cardiac dysfunction, further proving this point (Sharma et al., 2020; Hou et al., 2021). However, the detailed mechanism responsible for the metabolism change and thus cardiovascular disease in the context of estrogen deficiency, remains largely unknown. Estrogen plays important roles in the pathophysiological regulation of the intestinal functions. It is reported that estrogen receptors are expressed in enteric neurons, enteric glial cells, smooth muscle cells, and epithelial cells, indicating a role in regulating contractility of colon (D’Errico et al., 2018). Moreover, estrogen is found to be involved in the regulation of colonic epithelium function, including mucus secretion, gene expression, and exocytosis (Wada-Hiraike et al., 2006; Cuello-Carrion et al., 2010). On
the other hand, the microbiota has recently been found to be shaped by the host intestine epithelium via fecal miRNAs (Liu et al., 2016). It has been revealed that fecal miRNA acts as a dominant player in the gut microbiota (Thomas, 2016). These miRNAs can enter bacteria, regulate bacterial gene transcripts, affect bacterial growth and thus shape the gut microbiota (Liu et al., 2016).

In view of the above literature, we speculate that estrogen deficiency would possibly change the secreted miRNAs in the intestine, which in turn shapes the microbiota in an unfavorable phenotype toward cardiovascular disease. In this study, the microbiota change, its effects on cardiac function and the possible underlying mechanisms in the processes were systemically analyzed in the ovariectomized (OVX) mouse model and postmenopausal women.

Methods

Detailed methods are available in the online-only Supplemental Material. Requests by researchers to access the data, analytic methods, and study materials can be made to the corresponding author who manages the information.

Mice husbandry

The female C57BL/6J mice from the experimental animal center of the Fourth Military Medical University (Xi'an, China) were housed and processed in accordance with the Institutional Animal Care and Use Committee in the Fourth Military Medical University. C57BL/6J mice were housed in plastic cages in a controlled environment animal facility at 22 ± 2 °C with a 12-hour light/dark cycle. Mice from the same litter were randomly divided into different groups, and different groups of mice were grown in different cages with each cage of less than 5 mice.

OVX model

The OVX procedure was performed on 12-week-old C57BL/6J mice, and the age-matched C57BL/6J mice receiving a sham operation served as the controls. For the OVX surgery, the mice were anesthetized with an intraperitoneal injection of 1% sodium pentobarbital (40 mL/kg body weight). A 1-cm incision was made in the skin and back muscles parallel to the midline of the animal. Next, the ovaries were exposed, and the oviduct, including the ovarian blood vessels, was ligated followed by ovary removal. The incision in the back musculature was closed with nylon thread (Ethicon 4.0) and the skin was sutured, followed by disinfection. Throughout the surgical procedure, the mouse body temperature was maintained at 37 °C with a heating pad. The same surgeon did all surgery procedures. All the mice with either OVX or sham operation were fed with normal chow diet for additional 8 weeks.

Fecal microbiota transplantation and microsphere oral gavage

Fecal microbiota transplantation was done as described previously (Chassaing et al., 2015). Briefly, cecal contents from the normal control mice were suspended in 30% glycerol diluted in PBS (1.0 mL) and stocked at −80 °C until transplantation. Fecal microbiota transplantation (200 μL of fecal suspension) was orally delivered every other day in the mice after the sham or OVX operation (PBS as negative control), or treated with the negative control miRNA or miR-155 microspheres. The recipient mice didn't receive any antibiotics treatment before or after transplantation. Transplanted mice at indicated time were subjected to cardiac function and inflammation analysis as previously described.

Antibiotics treatment

To confirm whether the effects of colon specific delivery of miRNA antagonists rely on the colonic microbiome, miR-155 antagonists treated or control mice were additionally given penicillin plus vancomycin (1 mg antibiotic per g body weight per day) or no antibiotics (control) via drinking water. Eight weeks later, cardiac function and inflammation in both adipose tissue and heart were analyzed.

Mouse echocardiography

Mouse echocardiography was done as previously described (Yuan et al., 2010). Briefly, the mice were anesthetized by using inhaled 1% to 2% isoflurane gas and 100% oxygen via a circuit anesthesia apparatus. The mouse's core temperature was monitored using a rectal temperature probe, and an infrared heating lamp was used to maintain body temperature throughout the procedure. An electrocardiogram signal was also monitored through electrode pads on the heated platform. The heart rate was maintained at about 400 bpm by adjusting the isoflurane dose. The VisualSonics Vevo 2100 ultrasound instrument (VisualSonics Inc., Toronto, ON, Canada) armed with 30 MHz linear transducer was employed. The left ventricular (LV) systolic function was computed from the M-mode measurements. Pulsed Doppler studies of LV diastolic function were performed in the apical 4-chamber view with the Doppler cursor oriented parallel to the long-axis plane of the left ventricle. The sample volume was placed just below the level of the mitral annulus and adjusted to render the highest early diastolic flow velocity peak of the transmitral Doppler flow signal. The early and late diastolic peak velocity (E, A) and their ratio (E/A) were derived from the transmitral Doppler waveform.

Bacterial growth and incubation with miRNAs

To analyze the effects of miR-155 on the growth of Lactobacillus, Lactobacillus gasseri (ATCC 33323) grown in a sterile MRS (de Man, Rogosa and Sharpe) medium at 37 °C for 12 h in the presence or absence of different doses of miR-155.

qPCR analysis of the miRNA expression

RNA from tissues or bacteria was extracted using TRIzol, while RNA from the feces was isolated using Stool RNA kit (Omega,
Reverse transcription reaction was performed on 2 μg of each sample with miRCute miRNA qPCR Detection kit (Tiangen, Beijing, China) according to the manual instruction. The reverse-transcribed cDNA was used as the template for the amplification of interested miRNAs. U6 serves as internal control for mammalian cells. The relative expression was calculated using the 2^{-\Delta\Delta Ct} method. The primers were shown in Table S1.

**Uptake of miRNA by bacterium**

To confirm the capacity of miRNAs entering the bacterium, *Escherichia coli* were grown aerobically in LB medium together with PBS or FITC-labeled miRNA for immunofluorescence analysis. In addition, miRNA uptake efficiency was also analyzed by qPCR analysis of the miRNA abundance. About 1 mL *E. coli* in aliquot were treated with negative control miRNA or miR-155 or let-7g, and 12 h later, the *E. coli* was harvested for lysis and miRNA transcription. An equal amount of the reverse-transcribed RNA was included for qPCR analysis. The Ct value of the miRNA was calculated and compared.

**Statistical analysis**

The data were expressed as mean ± SEM otherwise indicated and the differences were analyzed by ANOVA with Tukey’s post hoc test or Student’s t-test using Graphpad Prism 7.0. Significance was considered at *p* < .05.

**Results**

**Decreased cardiac function and its relevance to the microbial change in OVX model**

To systematically analyze the phenotype of menopause-related estrogen deficiency, female mice were subjected to sham or OVX operation (Figure S1A). Consistent with previous reports (Stubbins et al., 2012; Varghese et al., 2021), OVX mice had a greater body weight and fat mass percentage than the sham mice (Figure S1B, C), while the food intake had no significant differences between sham and OVX mice (Figure S1D). Moreover, brown adipose tissue (BAT), subcutaneous fat tissue (SAT), and omental adipose tissue (OAT) were all much larger in the OVX mice than that in the sham group (Figure S1E–G). HE staining revealed that net weight increase of BAT in OVX mice could be attributed to the whitening of BAT (Figure S1H). Consistent with the obese phenotype of OVX mice, expression of tumor necrosis factor α (*Tnfα*), macrophage inflammatory protein (*Mip1*), and monocyte chemoattractant protein-1 (*Mcp1*) was also significantly increased in the OAT in OVX mice (Figure S1I). Consistent with the increase of cardiovascular disease risks in menopause women (Maas et al., 2021), the cardiac systolic and diastolic function was significantly compromised in the OVX group, as seen by the decreased short axis EF and E/A values (Figure S2A–C). Accordingly, there was increased expression of reactive oxygen species (ROS) (Figure S3A, B) and inflammatory genes, such as *Tnfα* and *Mcp1* (Figure S3F) in the heart. Flow cytometry analysis further revealed that more CD11b+ leukocytes and M1 macrophage infiltration in the heart of OVX mice (Figure S3C–E).

Microbiota is found to be a novel modulator in obesity and inflammation (Belda et al., 2022; Dabke et al., 2019). To explore the role of microbiota in OVX mice-related phenotype change referred above, we thus analyzed the microbiota via 16s RNA sequencing. The microbiota was significantly altered in the OVX mice, as seen from the Principal Component Analysis (Figure 1A). Surprisingly, the relative abundance of the Bacteroidetes increased, whereas the Firmicutes decreased (Figure 1B). Notably, *Lactobacillus* abundance also decreased in the OVX group (Figure 1C).

To further verify the role of microbiota in the OVX related phenotype, we transplant the gut microbiota from the OVX mice to the control sham mice, and vice versa (Figure 2A). Fecal transplantation significantly changed the microbiota content in the recipient mice as expected. Fecal transplantation between the Sham and OVX mice slightly changed the body weight and fat mass percentage, although without significance (Figure 2B, C). However, transplantation of the OVX mice derived microbiota significantly increased the inflammatory genes in both the adipose tissue and hearts of the sham control mice, though the fold change was not as big as the OVX itself. In contrast, transplantation of the sham control mice derived microbiota significantly decreased

**Figure 1.** Changes of microbiota in OVX mice model. (A) Principal Component Analysis on the relative abundance of bacterial phylum. Each point represents a sample, plotted by the second principal component on the Y-axis and the first principal component on the X-axis, which was colored by group. (B) The relative abundance of OTUs (%) in the fecal bacterial community. (C) The relative abundance of *Lactobacillus* in the fecal bacterial community. Data are expressed as mean ± SEM. **p < .01.
the inflammatory genes in both the adipose tissue and heart of the OVX mice (Figure 2D, E). Consistent with the inflammation remodeling, normal fecal microbiota partially restored the cardiac function of OVX mice (Figure 2F, G). Unexpectedly, OVX fecal microbiota didn’t alter the cardiac function of control mice significantly (Figure 2F, G), suggesting that fat mass increase and microbiota remodeling might synergistically impair the cardiac function.

To further explore the role of decreased *Lactobacillus* abundance in the OVX-associated cardiac dysfunction, OVX mice were orally supplemented with *Lactobacillus* (Figure S4A). As expected, *Lactobacillus* supplementation significantly decreased the inflammatory genes in both the adipose tissue and heart of the OVX mice (Figure S4B, C), while the body weight and fat mass didn’t affect (Figure S4D, E). Consistent with the inflammation remodeling, *Lactobacillus* supplementation partially restored the cardiac function of OVX mice (Figure S4F, G), though the E/A value didn’t show a significant difference.

All of these data raise the possibility that the microbiota might be remodeled toward an augmented inflammation signature in the context of OVX, and unraveling the factors remodeling the microbiota, especially the *Lactobacillus* abundance, would shed light on refining the microbiota toward better protective effects.

**Involvement of miRNAs in microbiota remodeling**

In addition to defensins, microRNAs are also considered as one key factor of the host intestine that might change the microbiota (Salzman et al., 2010; Liu et al., 2016). With the easy manipulation and intervention of miRNAs, our preliminary interest was focused on the roles of miRNA candidates. The top 18 abundantly expressed miRNAs in the colon epithelium and feces (namely miR-155, let-7g, miR-1224, miR-30a, miR-34c, miR-483, miR-710, miR-1929, miR-194, miR-21, miR-22, miR-378-3p, miR-148a, miR-192, miR-200a, miR-200b, and miR-574-5p; based on the study...
by Liu et al. (2016)) were selected for further study. The miRNA expression was determined using qPCR analysis. Among the miRNAs, miR-155 and let-7g changed robustly in OVX mice (Figure 3A). Validation results further showed miR-155 and let-7g expression were up-regulated in OVX mice in both the intestinal epithelium (Figure 3B, C) and the feces (Figure 3D, E), when compared with that in the sham-operated mice.

**Colon specific delivery of miR-155 antagonism protects the cardiac function via controlling the inflammation**

To specifically alter the miR-155 levels in the colon, Eudragit S100 functionalized microsphere was employed, in which Eudragit S100 could protect the encapsulated cargos from the destruction by the acid in the stomach (Mehta et al., 2013). Eudragit S100 was coated on the chitosan-based microspheres (Figure 5A). The resultant microspheres were about 1–2 µm in diameter and evenly distributed (Figure 5B, C). qPCR analysis confirmed high encapsulation efficiency of miR-155 in the microsphere (Figure 5D). Moreover, gauge delivery of the Eudragit S100 functionalized microsphere resulted in miRNAs specifically released in the colon feces and bacteria (Figure 5E, F). We encapsulated the cel-miR-54 into the microsphere and detected the transfer of cel-miR-54 into different organs in vivo via qPCR analysis. As expected, no obvious transfer of cel-miR-54 was found in the liver, spleen, adipose, heart, and other organs, except the intestinal epithelium (Figure S5). Taken together, we here developed a colon specific miRNA delivery strategy to alter the intestinal and fecal miRNA and to avoid degradation in the stomach and small intestine.

Next, we explored the effects of colon specific delivery of miR-155 on the microbiota, adipose and cardiac inflammation, and cardiac function (Figure S6A). miR-155 delivery significantly decreased the abundance of Lactobacillus, whereas had no significant effects on the total ratio of Bacteroidetes and Firmicutes (Figure S6B, C). In addition, body weight and fat mass percentage were not changed.
significantly (Figure S6D, E). Consistent with the decreased Lactobacillus, the expression of Tnfα, Mip1, and Mcp1 in the adipose tissue and heart increased significantly, while Lactobacillus supplementation reduced the inflammatory gene induction (Figure S6F, G). Similar changes were seen in the immune cell infiltration (Figure S6H, I). Notably, the cardiac function was not obviously changed by miR-155 delivery alone (Figure S6J, K), suggesting that miR-155 might act synergistically with fat mass increase to impair cardiac function.

In view of above data, we asked whether delivery of miR-155 antagonism would protect the heart from OVX-related damage via changing the microbiota (Figure 6A). Eudragit S100 functionalized microsphere mediated miR-155 antagonism delivery significantly increased the miR-155 antagonism in the colon feces and the bacteria (Figure S7A, B) in the OVX mice, although had no obvious change on the absolute level of miR-155 in both the feces and bacterium (Figure S7C, D). However, miR-155 related decrease of Lactobacillus in the OVX mice were nearly restored, with no obvious effects on either the ratio of Bacteroidetes/Firmicutes (Figure S7E, F), or the body weight and fat mass percentage (Figure S7G, H).

Consistent with the restored Lactobacillus, the expression of Tnfα, Mip1, and Mcp1 in the adipose tissue and heart decreased significantly after 8 weeks of the anti-miR-155 treatment (Figure 6B, C). Similarly, immune cell infiltration (Figure 6D, E) and ROS generation in the heart was also reduced (Figure S8A, B). Accordingly, the cardiac function was also restored, as shown by the increased EF and E/A values (Figure 6F, G). Moreover, antibiotics treatment nearly blunts the protective effects of the miR-155 antagonism, although antibiotics itself had minor detrimental effects on the inflammation and cardiac function (Figure 6B–G, S7G, H, S8A, B).

**Discussion**

CVD is now considered as the main cause of morbidity and mortality in developed countries (Tsao et al., 2022; Timmis et al., 2022). It is well established that the risk for CVD increases in women after menopause (Maas et al., 2021), which might be attributed to hormone change related obesity and MetS (Barros & Gustafsson, 2011). In the present study, we assessed the relationship between intestinal bacteria and cardiovascular function. The major findings of the
Decrease of Lactobacillus in the gut of OVX mouse model contributes to the increase of visceral fat mass, activated local and systemic inflammation, and thus cardiac dysfunction; 2) estrogen deficiency induced upregulation of miR-155 in the intestinal epithelium and thus the feces is capable to be endocytosed by bacteria in the intestine, which in turn shape the microbiota toward a detrimental signature; 3) Oral delivery of miR-155 antagonists by Eudragit S100 functionalized microspheres restores the protective microbiota and thus cardiac function.

Gut microbiota has been recently linked to CVD (Tang et al., 2019), while the detailed mechanisms regarding how microbiota changes and how changed microbiota alters the cardiovascular system, remain poorly understood. In this study, we found that estrogen deficiency results in altered miRNA profile in the intestinal epithelium and thus the feces, which is consistent with previous findings that estrogen/estrogen receptor signal acts as a potent gene expression regulator (Nagarajan et al., 2014). Moreover, our study further revealed that the secreted miRNAs from the intestine not only acts as indicator of the intestine health status, but also acts as an active regulator of the microbiota. Consistent with previous findings (Liu et al., 2016), we found that the altered miRNAs could be uptake by the bacteria, which in turn alters the microbiota diversity. Among the functional miRNAs in the feces, we identified that increase of miR-155 at least partially contributes to the detrimental signature of the gut microbiota in the OVX model. Accumulating studies have suggest that the gut microbiota correlates with the health status (Fan & Pedersen, 2021; de Vos et al., 2022), while the mechanisms are largely unknown. Our study here sets a good example how host health status alters the microbiota. For example, MetS is a prevalent and steady increase risk factor for CVD (Park et al., 2019). Obesity is the most important hallmark of MetS, which is considered to influence and reciprocally be influenced by gut microbiota (Aron-Wisnewsky et al., 2021; Ng et al., 2022). It is thus interesting to analyze the host factors shaping the microbiota in obesity and/or other MetS contexts. As to how increased miR-155 specifically reduced the Lactobacillus population, we hypothesize that miR-155 might specifically interact with the gene expression in the Lactobacillus via the abundant recognition sites in the genome, and thus interfere with the growth or survival. Future study using mutated miR-155 and RNA-seq analysis of the transcriptomic is would possibly confirm the assumption.

The OVX mice develop metabolic alterations that closely delineate the human MetS, such as dyslipidemia, obesity, and inflammation (Shinlapawittayatorn et al., 2022). Mechanistically, mice with ovariectomy are more prone to accumulate fat due to the lack of hormonal protection. The increase in adipose tissue mass is associated with activated inflammation, which in turn links to higher cardiovascular risk (Oikonomou & Antoniades, 2019). Majority of previous studies have reported that cardiac systolic function is not altered in OVX mice, which is different from our study. However, mechanism studies have suggested that the
cardiomyocytes were damaged to some extent under OVX or estrogen deprivation (Ren et al., 2003; Rattanasopa et al., 2015). In fact, there are also some studies revealing that the systolic function is compromised in OVX mice, especially when the mice had additional cardiovascular risks (Jia et al., 2017; Minta et al., 2018). The discrepancy might be due to the differences in echocardiography examination conditions and sensitivity. Besides the variation of culture conditions, such as the growth time and feeding diet, might also accounts. Of note, dead *Lactobacillus* may also show the similar but compromised anti-inflammatory effects as previously reported (uchinaka et al., 2018).

In this study, we found that miR-155 related reduction of *Lactobacillus* contributes to the increased fat accumulation, systemic inflammation, and thus cardiac dysfunction. However, we could not exclude the involvement of other microbial organisms. Previous studies have revealed that the metabolites from detailed bacteria are the main contributor of inflammation. For example, the choline-derived metabolite TMAO levels are strongly associated with atherosclerosis and cardiovascular risks (Tang et al., 2014; Wang et al., 2015). It is also reported that the gut microbiota is closely related to energy harvest and expenditure (Heiss & Olofsson, 2018; Fluhr et al., 2021). Increase in Firmicutes was significantly correlated to weight gain but not to total caloric intake (Turnbaugh et al., 2006), while *Lactobacillus* is considered to be beneficial for diminishing systemic and local inflammation (Pena & Versalovic, 2003). Our data here raise the possibility that the microbiota might be remodeled toward an obesity resistant signature at the sacrifice of *Lactobacillus* reduction. Our study also raises that *Lactobacillus* would beneficial for OVX related cardiac dysfunction via relieving inflammation. It is also interesting to explore whether *Lactobacillus* is beneficial to other context related MetS and associated cardiovascular dysfunction, such as high fat diet and genetic related obesity. Of note, the phenotype observed in OVX group could be either

---

**Figure 6.** Oral delivery of miR-155 antagonism protects the heart in OvX mice via microbiota remodeling. (A) Schematic representation of the experimental procedure. OvX mice were treated with negative control or anti-miR-155 twice a week for 8 weeks, together with or without antibiotics in drinking water (1 mg antibiotic per g body weight per day). n=5 for each group. (B, C) The expression of *Tnfα, Mip1*, and *Mcp1* in the adipose tissue (B) and heart (C) in mice received indicated treatments, as detected by qPCR. Data are expressed as mean±SEM of three biological replicates. (D, E) CD11b+ percentage (D) and M1 cell percentage (E) in mice treated as indicated. Data are expressed as mean±SEM of 3 mice per group. (F, G) Short axis EF value (F) and E/A value (G) in mice received indicated treatments. Data are expressed as mean±SEM of at least 5 mice per group. *p<.05, **p<.01.
from reduction of anti-inflammatory microbiota or increase of pro-inflammatory microbiota. Since proteobacteria increased dramatically in the OVX group, it is highly possible that proteobacteria might cause inflammation in OVX mice, which is worth of further study.

In this study, we found that miR-155 increase in OVX intestinal epithelium, which in turn promotes local and systemic inflammation via microbiota dysbiosis. Previously, miR-155 was found to be activated by inflammation in multiple systems (Wang et al., 2017; Jiang et al., 2019). These evidences together suggest a central moderator role of miR-155 in the feedback loop of inflammation-microbiota dysbiosis. It is important to note that besides miR-155, other miRNAs and defensins might be also involved in the estrogen deficiency related microbiota remodeling. It is also important to note that the effects of miR-155 delivery in Sham mice are not as obvious as the effects of anti-miR-155 delivery in OVX mice, which might be explained by potential synergistic role of miR-155 and omental adipose inflammation. Since miR-155 expression increase should be also observed in some other conditions, the observed miR-155-microbiota remodeling should be also related to these conditions with miR-155 highly expressed in the intestine.

Regarding the easy manipulation and targetable traits of miRNAs, we explored the possibility of colon specific delivery of miR-155 antagonist in restoring the microbiota dysbiosis and the associated cardiac dysfunction. The Eudragit S100 coating microsphere is intact in the stomach and intestine and thus protects the miRNA antagonists from degradation in the stomach and small intestine, resulting in specific release of the miRNAs in the colon (Jose et al., 2011). Compared with microbial transplantation, colon specific miRNA delivery-based microbiota restoration has multiple advantages. 1) The intestinal epithelium and the intestinal mucosal barrier that it secretes play a supportive role for the gut flora establishment (Faderl et al., 2015). Bacterium transplantation alone without supportive environment reconstruction might only have transient effects. However, targeting the mechanism how microbiota changes, might reestablish the microbial ecosystem from the preexisting microbiota. 2) Regarding the fecal origin, delivery of microbiota or specific bacterium is psychologically difficult for certain patients. In addition, as a live organism, the bacterium is difficult for manipulation, expansion, and transportation (Browne et al., 2016). In contrast, microsphere or other colon specific delivery strategies based miRNA delivery would overcome all of these disadvantages.

Conclusions

By using OVX mouse model, we for the first time revealed that altered colon epithelium-derived fecal miRNAs (mainly increased miR-155) were one of the causes of diminished Lactobacillus in the gut of the OVX mice. Orally colon specific delivery of miR-155 antagonist encapsulated in the Eudragit S100 functionalized microspheres restores the beneficial microbiota and thus protects the cardiac function.

Acknowledgements

We are grateful for the technical help from Qianqian Chen. We would also express our thanks for all the lab members for critical reading of the manuscript.
Disclosure statement

No potential conflict of interest was reported by the authors.

Funding

This study was funded by National Natural Science Foundation of China (NSFC 81901861, 81901751, and 81671690), the Fund of Shaanxi Provincial Health Research (2018A013) and the Innovative Talent Promotion Program of Shaanxi Province (2022KJXX-106).

References

Aron-Wisnewsky J, Warmbrunn MV, Nieuwdorp M, Clément K. (2021). Metabolism and metabolic disorders and the microbiome: the intestinal microbiota associated with obesity, lipid metabolism, and metabolic health-pathophysiology and therapeutic strategies. Gastroenterology 160:573–99.

Barros RP, Gustafsson JA. (2011). Estrogen receptors and the metabolic network. Cell Metab 14:289–99.

Belda E, Voland L, Tremaroli V, The MetaCardis Consortium, et al. (2022). Impairment of gut microbial butyrophilin metabolism and host butyrophilin status in severe obesity: effect of butyrophilin and prebiotic supplementation on improved metabolism. Gut gutjnl-2021-325753.

Browne HP, Forster SC, Aneyne BO, et al. (2016). Culturing of ‘unculturable’ human microbiota reveals novel taxa and extensive sporulation. Nature 533:543–6.

Chassaing B, Koren O, Goodrich JK, et al. (2015). Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome. Nature 519:92–6.

Cuello-Carrion FD, Troncoso M, Guzunia E, et al. (2010). Estrogens regulate the expression of NHERF1 in normal colon during the reproductive cycle of Wistar rats. Histochem Cell Biol 134:623–30.

Dabke K, Hendrick G, Devkota S. (2019). The gut microbiome and metabolic syndrome. J Clin Invest 129:4050–7.

de Vos WM, Tilg H, Van Hul M, Cani PD. (2022). Gut microbiome and health: mechanistic insights. Gut 71:1020–32.

D’Errico F, Gouverse G, Dai Y, et al. (2018). Estrogen receptor beta controls proliferation of enteric glia and differentiation of neurons in the myenteric plexus after damage. Proc Natl Acad Sci U S A 115:5798–803.

Faderl M, Noti M, Corazza N, Mueller C. (2015). Keeping bugs in check: the mucus layer as a critical component in maintaining intestinal homeostasis. IUBMB Life 67:275–85.

Fan Y, Pedersen O. (2021). Gut microbiota in human metabolic health and disease. Nat Rev Microbiol 19:55–71.

Fluhr L, Mor U, Kolodziejczyk AA, et al. (2021). Gut microbiota modulates weight gain in mice after discontinued smoke exposure. Nature 600:713–9.

Heiss CN, Olofsson LE. (2018). Gut microbiota-dependent modulation of energy metabolism. J Innate Immun 10:163–71.

Hou N, Huang Y, Cai SA, et al. (2021). Puerarin ameliorated pressure overload-induced cardiac hypertrophy in ovariectomized rats through activation of the PPARalpha/PGC-1 pathway. Acta Pharmacol Sin 42:55–67.

Jia C, Chen H, Wei M, et al. (2017). Gold nanoparticle-based miR155 antagonist macrophage delivery restores the cardiac function in ovariectomized diabetic mouse model. Int J Nanomedicine 12:4963–79.

Jiang K, Yang J, Guo S, et al. (2019). Peripheral circulating exosome-mediated delivery of miR-155 as a novel mechanism for acute lung inflammation. Mol Ther 27:1758–71.

Jose S, Prema MT, Chacko AJ, et al. (2011). Colon specific chitosan microspheres for chronotherapy of chronic stable angina. Colloids Surf B Biointerfaces 83:277–83.

Kazemian N, Mahmoudi M, Halperin F, et al. (2020). Gut microbiota and cardiovascular disease: opportunities and challenges. Microbiome 8:36.

Liu S, da Cunha AP, Rezende RM, et al. (2016). The host shapes the gut microbiota via fecal microRNA. Cell Host Microbe 19:32–43.

Liuozzo G, Galunto L. (2021). Modulating the gut microbiome with dietary interventions to reduce cardiometabolic disease risk. Eur Heart J 42:2152–3.

Maas A, Rosano G, Cifkova R, et al. (2021). Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: a consensus document from European cardiologists, gynaecologists, and endocrinologists. Eur Heart J 42:967–84.

Mauvais-Jarvis F, Clegg DJ, Hevener AL. (2013). The role of estrogens in control of energy balance and glucose homeostasis. Endocr Rev 34:309–38.

Mehta R, Chawla A, Sharma P, Pawar P. (2013). Formulation and in vitro evaluation of Eudragit S-100 coated naproxen matrix tablets for colon-targeted drug delivery system. J Adv Pharmac Technol Res 4:31–41.

Minta W, Palese S, Mantor D, et al. (2018). Estrogen deprivation aggravates cardiometabolic dysfunction in obese-insulin resistant rats through the impairment of cardiac mitochondrial dynamics. Exp Gerontol 103:107–14.

Nagarajan S, Hossan T, Alawi M, et al. (2014). Bromodomain protein BRD4 is required for estrogen receptor-dependent enhancer activation and gene transcription. Cell Rep 8:460–9.

Nam HS. (2019). Gut microbiota and ischemic stroke: the role of trimethylamine N-oxide. J Stroke 21:151–9.

Ng SC, Xu Z, Mak JWY, et al. (2022). Microbiota engraffment after faecal microbiota transplantation in obese subjects with type 2 diabetes: a 24-week, double-blind, randomised controlled trial. Gut 71:716–23.

Oikonomou EK, Antoniades C. (2019). The role of adipose tissue in cardiovascular health and disease. Nat Rev Cardiol 16:83–99.

Park S, Lee S, Kim Y, et al. (2019). Altered risk for cardiovascular events with changes in the metabolic syndrome status: a nationwide population-based study of approximately 10 million persons. Ann Intern Med 171:875–84.

Pena JA, Versalovic J. (2003). Lactobacillus rhamnosus GG decreases TNF-alpha production in lipopolysaccharide-activated murine macrophages by a contact-independent mechanism. Cell Microbiol 5:277–85.

Rattanasopa C, Phungphong S, Wattanapermpool J, Bupha-Intr T. (2015). Significant role of estrogen in maintaining cardiac mitochondrial functions. J Steroid Biochem Mol Biol 147:1–9.

Ren J, Hintz KK, Roughhead ZK, et al. (2003). Impact of estrogen replacement on ventricular myocyte contractile function and protein kinase B/Akt activation. Am J Physiol Heart Circ Physiol 284:H1808–9.

Salzman NH, Hung K, Haribhai D, et al. (2010). Enteric defensins are essential regulators of intestinal microbial ecology. Nat Immunol 11:76–83.

Sharma G, Hu C, Staquicini DI, et al. (2020). Preclinical efficacy of the GPER-selective agonist G-1 in mouse models of obesity and diabetes. Sci Transl Med 12(528):5956.

Shinlapawittayatorn K, Pongkan W, Sivasinprasasn S, Chattipakorn SC, et al. (2020). Preclinical efficacy of the colon-targeted drug delivery system. J Adv Pharmac Technol Res 4:31–41.

Shinlapawittayatorn K, Pongkan W, Sivasinprasasn S, Chattipakorn SC, et al. (2020). Preclinical efficacy of the colon-targeted drug delivery system. J Adv Pharmac Technol Res 4:31–41.

Shrestha G, Nam HS. (2019). Gut microbiota and ischemic stroke: the role of trimethylamine N-oxide. J Stroke 21:151–9.

Tang WH, Wang Z, Fan Y, et al. (2014). Prognostic value of elevated levels of intestinal microbe-generated metabolite trimethylamine-N-oxide in patients with heart failure: refining the gut hypothesis. J Am Coll Cardiol 64:1908–14.

Tang WHW, Backhed F, Landmesser U, Hazen SL. (2019). Intestinal microbiota in cardiovascular health and disease: JACC state-of-the-art review. J Am Coll Cardiol 73:2089–105.
Thomas H. (2016). Gut microbiota: host faecal miRNA regulates gut microbiota. Nat Rev Gastroenterol Hepatol 13:122–3.
Timmis A, Vardas P, Townsend N, Atlas Writing Group, European Society of Cardiology, et al. (2022). European Society of Cardiology: cardiovascular disease statistics 2021. Eur Heart J 43:716–99.
Tsao CW, Aday AW, Almarzooq ZI, et al. (2022). Heart Disease and Stroke Statistics-2022 update: a report from the American Heart Association. Circulation 145:e153–e639.
Turnbaugh PJ, Ley RE, Mahowald MA, et al. (2006). An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444:1027–31.
Uchinaka A, Azuma N, Mizumoto H, et al. (2018). Anti-inflammatory effects of heat-killed Lactobacillus plantarum L-137 on cardiac and adipose tissue in rats with metabolic syndrome. Sci Rep 8:8156.
Varghese M, Griffin C, Abrishami S, et al. (2021). Sex hormones regulate metainflammation in diet-induced obesity in mice. J Biol Chem 297:101229.
Wada-Hiraike O, Imamov O, Hiraike H, et al. (2006). Role of estrogen receptor beta in colonic epithelium. Proc Natl Acad Sci U S A 103:2959–64.
Wang C, Zhang C, Liu L, et al. (2017). Macrophage-derived miR-155-containing exosomes suppress fibroblast proliferation and promote fibroblast inflammation during cardiac injury. Mol Ther 25:192–204.
Wang Z, Roberts AB, Buffa JA, et al. (2015). Non-lethal inhibition of gut microbial trimethylamine production for the treatment of atherosclerosis. Cell 163:1585–95.
Yuan L, Wang T, Liu F, et al. (2010). An evaluation of transmitral and pulmonary venous Doppler indices for assessing murine left ventricular diastolic function. J Am Soc Echocardiogr 23:887–97.